(Q43263384)

17 November 2017

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease (English)

1 reference

17 November 2017

1 reference

ChEBI release 2020-05-28

1 reference

4

Charles N Bernstein

1 reference

17 November 2017

Alan L Buchman

1

1 reference

17 November 2017

Seymour Katz

2

1 reference

17 November 2017

John C Fang

3

1 reference

17 November 2017

Souheil G Abou-Assi

5

1 reference

17 November 2017

Teduglutide Study Group

6

1 reference

17 November 2017

1 June 2010

1 reference

Inflammatory Bowel Diseases

17 November 2017

1 reference

17 November 2017

16

1 reference

17 November 2017

6

1 reference

17 November 2017

962-973

1 reference

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

17 November 2017

1 reference

Disability from inflammatory bowel disease among employees in West Germany

21 January 2018

1 reference

Unemployment and disability in patients with moderately to severely active Crohn's disease

21 January 2018

1 reference

Crohn's disease: why the disparity in mortality?

21 January 2018

1 reference

Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort

21 January 2018

1 reference

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

Tumor necrosis factor: biology and therapeutic inhibitors

21 January 2018

1 reference

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow

21 January 2018

1 reference

GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors

21 January 2018

1 reference

Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2

21 January 2018

1 reference

Modulation of specific intestinal epithelial progenitors by enteric neurons

21 January 2018

1 reference

Glucagon-like peptide-2: divergent signaling pathways

21 January 2018

1 reference

Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa

21 January 2018

1 reference

Enteroendocrine localization of GLP-2 receptor expression in humans and rodents

21 January 2018

1 reference

Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.

21 January 2018

1 reference

Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice.

21 January 2018

1 reference

The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis

21 January 2018

1 reference

Glucagon-like peptide-2 protects against TPN-induced intestinal hexose malabsorption in enterally refed piglets

21 January 2018

1 reference

Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.

21 January 2018

1 reference

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients

21 January 2018

1 reference

Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse

21 January 2018

1 reference

Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease

21 January 2018

1 reference

Plasma citrulline: a marker of enterocyte mass in villous atrophy-associated small bowel disease

21 January 2018

1 reference

Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans

21 January 2018

1 reference

Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients

21 January 2018

1 reference

Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy

21 January 2018

1 reference

Blood citrulline level is an exclusionary marker for significant acute rejection after intestinal transplantation

21 January 2018

1 reference

Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation.

21 January 2018

1 reference

A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease

21 January 2018

1 reference

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis

21 January 2018

1 reference

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease

21 January 2018

1 reference

IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior

21 January 2018

1 reference

Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status.

21 January 2018

1 reference

Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health.

21 January 2018

1 reference

Glucagon-like peptide-2 increases mesenteric blood flow in humans.

21 January 2018

1 reference

Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF--beta-mediated effect

21 January 2018

1 reference

Mediators of glucagon-like peptide 2-induced blood flow: responses in different vascular sites.

21 January 2018

1 reference

Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.

21 January 2018

1 reference

Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY.

21 January 2018

1 reference

Localization and Activation of Glucagon-Like Peptide-2 Receptors on Vagal Afferents in the Rat

21 January 2018

1 reference

Glucagon-Like Peptide 2 Dose-Dependently Activates Intestinal Cell Survival and Proliferation in Neonatal Piglets

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.21117

1 reference

17 November 2017

1 reference